Takeda, Affymax ink supply deal for anemia drug
(Reuters) - Affymax Inc said its partner Takeda Pharmaceutical Co Ltd entered into an agreement to supply their anemia drug to U.S. dialysis centers operated by Fresenius Medical Care.
Germany's Fresenius will initially adopt the drug Omontys, which treats anemia in adult patients with chronic kidney disease undergoing dialysis, at more than 100 dialysis centers in the United States.
The dialysis provider will expand the program to additional centers based on feedback received over the next few weeks.
The agreement between Japan's Takeda and Fresenius runs till April 2013.
Omontys received approval from U.S. Food and Drug Administration on March 27.
Shares of Affymax rose 13 percent to $13.54 in early morning trade on the Nasdaq.
(Reporting By Pallavi Ail; Editing by Supriya Kurane)
Thousands line up to say goodbye to Nelson Mandela, whose body is lying in state in Pretoria. Slideshow
WASHINGTON - U.S. small business sentiment bounced back from a seven-month low in November, with owners setting their sights on creating more jobs and expanding operations.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.